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Abstract
Background: Pregabalin is a therapeutic drug for neuropathic pain that is associated with somnolence and
dizziness. These adverse events are often experienced shortly after initiating pregabalin, and may lead to treatment
discontinuation. The purpose of this study was to explore factors that influence the incidence of somnolence and
dizziness induced by pregabalin, and to identify patients at higher risk of adverse events.
Methods: A retrospective analysis was conducted of patient characteristics (age, gender, renal function, initial
daily dose of pregabalin, co-administration of strong opioids and hypnotics) and the incidence of somnolence
and dizziness during the first week of pregabalin treatment. An electronic chart was used to collect data from
204 inpatients prescribed pregabalin at Nagoya University Hospital from June 2011 to November 2012.
Results: Among 36 patients who regularly received strong opioids, 18 (50.0 %) reported somnolence or dizziness
during the first week of pregabalin treatment. The remaining 168 patients did not regularly receive strong
opioids, and 25 (14.9 %) had an adverse event. In multivariate analysis, age (≧65 years, adjusted odds ratio: 2.507,
95 % CI: 1.164-5.397, p = 0.019) and regular co-administration of strong opioids (adjusted odds ratio: 5.507, 95 %
CI: 2.460-12.328, p < 0.001) correlated with somnolence or dizziness.
Conclusions: These data suggest that age (≧65 years) and co-administration of strong opioids are risk factors for
somnolence or dizziness during pregabalin treatment for neuropathic pain. More careful dose titration is
recommended for elderly patients and those receiving concomitant strong opioids.
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Background
The World Health Organization (WHO) analgesic ladder
has been demonstrated to be effective for the treatment
of cancer pain [1]. Patients with moderate-to-severe
pain are candidates for starting strong opioid agents.
However, because neuropathic cancer pain is resistant
to opioids, certain adjuvant drugs are administered, in-
cluding pregabalin, gabapentin, and duloxetine, and
these have been shown to be effective [2–4].
Pregabalin is indicated for the management of neuro-
pathic pain associated with diabetic peripheral neur-
opathy, postherpetic neuralgia, and spinal cord injury,
and for the treatment of fibromyalgia. Pregabalin was
first developed as an antiepileptic drug, and its efficacy
for various types of neuropathic pain was demonstrated
at a later time [5]. The efficacy of pregabalin for neuro-
pathic pain has been attributed to modulation of glutam-
ate release from hyperexcited neurons via binding to the
alfa-2-delta (α2-δ) subunit of voltage-gated calcium
channels, which modulates calcium influx to presynaptic
terminals [6, 7]. Pharmacokinetic studies of pregabalin
reveal that it is more than 90 % renally excreted as un-
changed drug [8]. Accordingly, its clearance is reduced
in patients with renal impairment [9].
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The most common adverse events related to pregaba-
lin treatment are somnolence and dizziness, which in-
crease in a dose-dependent manner and represent the
most frequent reasons for discontinuation of treatment
[10–12]. Previous studies indicate that somnolence and
dizziness associated with pregabalin therapy are transi-
ent, and most commonly reported in the first week of
treatment, with a lower incidence thereafter [11–14].
Thus, careful dose titration to the highest tolerable
dose is the most appropriate approach.
Neuropathic cancer pain is a frequent complication of
cancer or its treatment, with approximately one-third of
cancer pain cases involving a neuropathic component
[15, 16]. Previous studies have demonstrated that adjuvant
drugs, such as pregabalin, are efficacious for the treatment
of neuropathic pain, although the majority of data have
been obtained from non-cancer studies [17–20]. Recently,
it has been reported that the neuropathic component
of cancer pain responds more effectively to pregabalin
than to strong opioids such as transdermal fentanyl
[21]. Adjuvant drugs for the treatment of neuropathic
cancer pain are included in recent clinical recommen-
dations, usually as an add-on to opioids [22]. Therefore,
cancer patients with pain who receive pregabalin treat-
ment are often treated with opioids, which have inhibitory
effects on the central nervous system. It is assumed that
the combination of pregabalin with opioids may potentiate
somnolence and dizziness.
The purpose of this study was to explore risk factors
that influence the incidence of somnolence and dizziness
induced by pregabalin, and to identify patients at higher




This retrospective study was approved by the ethical
committee of Nagoya University Hospital. Inpatients who
were prescribed pregabalin (Lyrica® capsule) at Nagoya
University Hospital from June 2011 to November 2012
were included. Exclusion criteria included patients who
had initiated pregabalin treatment as an outpatient or
in other hospitals, and presented somnolence, dizziness,
or consciousness disorder caused by medication or
electrolyte imbalance such as hypercalcemia at the time
starting pregabalin treatment.
Patients’ baseline characteristics, including age, gender,
renal function, neuropathic pain origin, initial dose of
pregabalin (mg per day), co-administration of strong
opioids (morphine, oxycodone, and fentanyl, except
when used solely for rescue), co-administration of hyp-
notics, and the incidence of somenolence and dizziness
during the first week of pregabalin treatment were retro-
spectively examined using an electronic chart. Creatinine
clearance (CLcr), as a measure of renal function, was
evaluated using the Cockcroft-Gault equation as follows:
CLcr mL=minð Þ ¼ 140 ‐ ageð Þ  weight kgð Þ = 72
 serum creatinine mg=dLð Þ
 0:85 if femaleð Þ
Statistical analysis
To identify factors associated with the incidence of
adverse events (somnolence or dizziness), univariate
analysis was performed using age, gender, regular co-
administration of strong opioids, renal function, initial
dose of pregabalin, pregabalin dose group, and regular
co-administration of hypnotics as independent vari-
ables. Factors with a p-value <0.05 in univariate analysis
were evaluated as potential covariates in multivariate
analysis using logistic regression modeling. All statis-
tical analyses were performed using SPSS version 22
(SPSS Inc., USA). P-values <0.05 were considered to
denote statistically significant differences.
Results
Patient characteristics
The study included 204 patients [male: 123 (60.3 %), fe-
male: 81 (39.7 %)] with a median age of 61 years (range:
18–92). Thirty-six patients (17.6 %) were regularly ad-
ministered strong opioids (fentanyl: n = 17, oxycodone:
n = 16, morphine: n = 3). The median dose of regular
opioid (converted to oral morphine) was 60 mg/day
(range: 15-300 mg/day). Initial dosages of pregabalin
were 25 (n = 4), 50 (n = 3), 75 (n = 73), and 150 mg/day
(n = 124) (Table 1).
Relationship between renal function and adverse events
Initial doses of pregabalin according to renal function
(CLcr) are depicted in Table 2. In patients with normal
renal function (CLcr≧60 mL/min), a total daily dose of
150 mg pregabalin is recommended initially. In pa-
tients with impaired renal function, the total daily
dose of pregabalin was reduced according to the de-
gree of renal function (60 > CLcr≧30 mL/min: 75 mg/
day, 30 > CLcr≧15 mL/min: 25–50 mg/day, 15 mL/
min > CLcr: 25 mg/day).
Based on the initial dosing recommendations for dif-
fering degrees of renal function in the prescribing infor-
mation of Lyrica® capsules [10], patients were divided
into three groups: "high dose group", "regular dose
group", and "low dose group". The incidence of somno-
lence or dizziness in each group is presented in Table 3.
Seven (43.8 %) of 16 patients in the high dose group, 28
(21.1 %) of 133 patients in the regular dose group, and 8
(14.5 %) of 55 patients in low dose group reported som-
nolence or dizziness.
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Univariate analysis
Table 4 displays the relationship between each factor
(age, gender, regular co-administration of strong opioids,
renal function (CLcr), initial dose of pregabalin, pregaba-
lin dose group, and regular co-administration of hyp-
notics) and incidence of adverse events (somnolence or
dizziness) determined by univariate analysis. Among pa-
tients who regularly used strong opioids with pregabalin,
18 (50.0 %) of 36 exhibited somnolence or dizziness
during the first week of pregabalin therapy. In contrast,
adverse events were reported by only 25 (14.9 %) of
the 168 patients who did not regularly receive strong
opioids. Age (≧65 years), regular co-administration of
strong opioids, renal function (CLcr < 60 mL/min), and
high pregabalin doses were related to adverse events.
Among these factors, regular co-administration of
strong opioids had the highest odds ratio (odds ratio:
5.720, 95 % CI: 2.624-12.470, p < 0.001).
Multivariate analysis
The results of multivariate analysis are presented in
Table 5. Independent variables included: age, regular co-
administration of strong opioids, renal function (CLcr),
and pregabalin dose group. The dependent variable was
incidence of adverse events (somnolence or dizziness).
Age (≧65 years, adjusted odds ratio: 2.507, 95 % CI:
1.164-5.397, p = 0.019) and regular co-administration of
strong opioids (adjusted odds ratio: 5.507, 95 % CI:





Male, n(%) 123 (60.3)
Female , n(%) 81 (39.7)
Median CLcra, mL/min 88.7
NPb origin
Cancer related NP, n(%) 55 (27.0)
Chemotherapy related NP, n(%) 24 (11.7)
Non-cancer related NP, n(%) 125 (61.3)
Regular strong opioid




Median dosec (range), mg/day 60 (15–300)
no, n(%) 168 (82.4)
Initial dose of pregabalin
150 mg/day, n(%) 124 (60.8)
75 mg/day, n(%) 73 (35.8)
50 mg/day, n(%) 3 (1.5)
25 mg/day, n(%) 4 (1.9)
aCLcr: creatinine clearance using the Cockcroft-Gault equation
bNP: neuropathic pain
cconverted to oral morphine
Table 2 Distribution of initial daily doses of pregabalin
according to renal function
Renal function Initial dose of pregabalin (per day)
25 mg 50 mg 75 mg 150 mg
(n = 4) (n = 3) (n = 73) (n = 124)
CLcra≧60 3 2 49 112
60 > CLcr≧30 0 1 20 11
30 > CLcr≧15 1 0 4 1
15 > CLcr 0 0 0 0
aCLcr: creatinine clearance (mL/min) using the Cockcroft-Gault equation
Table 3 Adverse events according to pregabalin dose group
Pregabalin dose
group
Adverse eventa, n Incidence of
adverse event, %(+) (−)
High 7 9 43.8
Regular 28 105 21.1
Low 8 47 14.5
aAdverse event: somnolence or dizziness





95 % CI P-value
(+) (−)
Age ≧65 26 55 2.948 1.474-5.892 0.002
<65 17 106




yes 18 18 5.720 2.624-12.470 <0.001
no 25 143
CLcr <60 mL/min 13 25 2.357 1.083-5.133 0.031
≧60 mL/min 30 136
Initial dose
of pregabalin
150 mg/day 30 94 1.645 0.799-3.387 0.177
<150 mg/day 13 67
Pregabalin
dose group
high 7 9 3.284 1.146-9.407 0.027
regular/low 36 152
Hypnotics yes 8 20 1.611 0.655-3.962 0.299
no 35 141
aAdverse event: somnolence or dizziness
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2.460-12.328, p < 0.001) were significantly associated
with the incidence of somnolence or dizziness.
Discussion
Data from this study suggest that age and co-
administration of regular strong opioids are risk factors
for somnolence or dizziness in patients treated with
pregabalin. Elderly patients often present with impair-
ments in drug metabolism and excretion. Pregabalin
undergoes renal excretion as an unchanged drug without
hepatic metabolism [8, 23]. However, in the present
multivariate analysis, renal impairment was not associ-
ated with the occurrence of somnolence and dizziness.
In an analysis of patient-level data from 31 clinical trials
of pregabalin, the risk of somnolence and dizziness was
higher in elderly patients compared with that of other
adverse events (for example, weight gain and dry mouth)
[11]. This suggests that elderly patients on pregabalin
therapy may have a higher risk of central nervous system
adverse events such as somnolence and dizziness, but
these events may not be due to renal impairment.
It has been reported that the AUC (area under the
blood concentration curve) of gabapentin, a similar drug to
pregabalin, is elevated when gabapentin is co-administrated
with morphine [24]. This is explained by the increased
absorption of gabapentin because of morphine-induced
gastrointestinal hypomotility. The pharmacokinetic
properties of pregabalin are different from those of
gabapentin. Pregabalin has greater than 90 % bioavail-
ability, regardless of dosage, while the bioavailability of
gabapentin decreases as the dose increases. Therefore,
the extent of gastrointestinal absorption of pregabalin,
which has high bioavailability, may not be altered by
concomitant opioid administration. Pharmacodynamic,
but not pharmacokinetic interaction could be suggested
in co-administration of pregabalin and opioid. Pregaba-
lin is structurally related to gamma-aminobutyric acid
(GABA), but it does not bind to GABAA, GABAB, or
benzodiazepine receptors [6]. Gabapentin maintains
and potentiates GABAergic systems, and it suppresses
neuronal activity by increasing GABA levels in the
brain [25, 26]. Thus, it is possible that the modulating
effects of pregabalin on GABAergic systems influence
the sedative effects of opioids in an additive manner,
exacerbating somnolence and dizziness. However, co-
administration of hypnotics was not associated with the
incidence of somnolence and dizziness significantly in
our study.
In a previous report, the impact of disease conditions
on the incidence of pregabalin-associated adverse events
was analyzed [11]. The incidence of somnolence and diz-
ziness in cancer patients with neuropathic pain who re-
ceived pregabalin treatment was not different from that
observed for other diseases such as diabetic peripheral
neuropathy and postherpetic neuralgia. Although no
clear relationship was observed between cancer and the
incidence of somnolence and dizziness in that report,
administration of pregabalin to patients on regular
strong opioids increased the incidence of these adverse
events according to our data.
Previously, it has been suggested that the incidence of
somnolence and dizziness in patients treated with prega-
balin increases in a dose-dependent manner [11, 12].
However, in the present study, the initial dose of prega-
balin did not have a significant impact on adverse event
rates. Differences between studies include longer obser-
vation periods of several weeks, and more variable main-
tenance doses of pregabalin (maximum: 600 mg/day).
Thus, it is likely that the initial dose of pregabalin has
minimal impact on the incidence of somnolence and
dizziness.
Furthermore, high pregabalin doses were not associ-
ated with a higher incidence of somnolence or dizziness,
using the initial dose recommendations based on renal
function. Although the initial dose of pregabalin was ad-
justed according to renal function, some patients re-
ceived high or low doses of pregabalin. Under such
conditions, dose of pregabalin did not have a significant
impact on adverse events. This aspect may need to be
studied for a longer observation period in a larger sam-
ple size using high doses. In the present study, the ob-
servation period was restricted to one week and the
sample size was small (high dose group; n = 16).
The present study has limitations, including the retro-
spective, single-center design. Further prospective stud-
ies with a larger sample size are needed. Also, effect of
hypnotics prescribed as needed is not taken into account
in this study because of the limited data.
Conclusions
In conclusion, these findings suggest that age (≧65 years)
and co-administration of strong opioids are risk factors
for somnolence or dizziness in patients on pregabalin
treatment. Thus, more careful dose titration of prega-
balin for neuropathic pain therapy is recommended in
elderly patients, and those who receive strong opioids
concomitantly.
Table 5 Multivariate analysis
Factor Adjusted
odds ratio
95 % CI P-value
Age ≧65 2.507 1.164-5.397 0.019
Regular strong opioid yes 5.507 2.460-12.328 <0.001
CLcr <60 mL/min 1.138 0.380-3.409 0.817
Pregabalin dose group high 2.172 0.518-9.099 0.289
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